Guggenheim Reiterates Buy Rating for uniQure (NASDAQ:QURE)

Guggenheim restated their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a report published on Monday,Benzinga reports. Guggenheim currently has a $28.00 price target on the biotechnology company's stock.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reissued an "outperform" rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. StockNews.com upgraded uniQure to a "sell" rating in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research note on Monday, April 21st. Finally, Chardan Capital restated a "buy" rating and issued a $38.00 price objective on shares of uniQure in a research note on Monday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Stock Up 4.7%

Shares of NASDAQ:QURE traded up $0.60 on Monday, hitting $13.25. 1,149,338 shares of the company traded hands, compared to its average volume of 1,872,298. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50 day simple moving average of $12.25 and a 200-day simple moving average of $12.19. The company has a market cap of $725.78 million, a PE ratio of -2.67 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. As a group, research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity

In other news, CFO Christian Klemt sold 14,341 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This trade represents a 8.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares of the company's stock, valued at approximately $6,703,461.66. This represents a 4.17% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by insiders.

Institutional Trading of uniQure

A number of large investors have recently bought and sold shares of QURE. Twin Tree Management LP acquired a new stake in uniQure during the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC acquired a new stake in uniQure during the 4th quarter worth approximately $88,000. Mraz Amerine & Associates Inc. acquired a new stake in uniQure during the 1st quarter worth approximately $106,000. OMERS ADMINISTRATION Corp acquired a new stake in uniQure during the 1st quarter worth approximately $152,000. Finally, ADAR1 Capital Management LLC acquired a new stake in uniQure during the 4th quarter worth approximately $177,000. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.